Lotus Pharmaceuticals Co (美時化學製藥) yesterday gave an upbeat outlook for global sales of its generic drugs this quarter, as its marketing network now covers more than 130 countries.
Third-quarter sales grew 24.5 percent from a year earlier to NT$1.96 billion (US$64.21 million), mainly boosted by robust US sales of its buprenorphine/naloxone tablets, which are sold under the name Desud Plus, for the treatment of narcotic addiction, the generic drugmaker said.
The company’s sales of lenalidomide for treatment of blood cancer also advanced in Europe, while sales of other drugs in other regions — including Southeast Asia and Africa — also reported rapid growth, Lotus acting spokeswoman Nadiya Chen (陳荻雅) told the Taipei Times by telephone.
International sales used to account for only a single-digit percent of its total sales, but they had risen to about 21 percent as of the end of September, Chen said.
The company expects its international sales to continue growing as it has a chance of having its Desud Plus included in US public health insurance plans after the US government last month said it would include more generic drugs.
Desud Plus is currently only covered by private health insurance plans in the US, as all narcotic addiction treatment drugs included in the public plans are branded medicines, it said.
The company said it hopes to see Desud Plus secure a higher market share in the US next year.
It is also working on gradually enhancing its marketing programs for lenalidomide in South Africa and east Europe, where it faces fewer competitors, as well as promoting gefitinib for lung cancer treatment and vinorelbine for breast cancer treatment in Europe.
Compared with the Europe and the US, the company’s overall sales of generic drugs in Asia have remained comparatively flat in the past few years due to intense competition, Chen said.
To spur new growth, the company next year plans to introduce two new drugs — the anti-obesity drug Qsymia in South Korea and a drug for osteoporosis treatment in Southeast Asia, Chen said.
For the first nine months of this year, the company’s cumulative revenue rose 28.4 percent annually to NT$6.04 billion, with gross margin improving mildly from 48 percent to 50 percent.
Cumulative net profit over the nine-month period totaled NT$523 million, increasing 18 times from a year earlier.
Earnings per share hit a new record of NT$2.17, compared with NT$0.11 a year earlier, company data showed.
The company, which at the end of last month received approval to move from the smaller Taipei Exchange to the main Taiwan Stock Exchange, has no plans to raise new capital for the time being, Chen said.
The share price was not ideal, she added.
ENERGY ISSUES: The TSIA urged the government to increase natural gas and helium reserves to reduce the impact of the Middle East war on semiconductor supply stability Chip testing and packaging service provider ASE Technology Holding Co (日月光投控) yesterday said it planned to invest more than NT$100 billion (US$3.15 billion) in building a new advanced chip testing facility in Kaohsiung to keep up with customer demand driven by the artificial intelligence (AI) boom. That would be included in the company’s capital expenditure budget next year, ASE said. There is also room to raise this year’s capital spending budget from a record-high US$7 billion estimated three months ago, it added. ASE would have six factories under construction this year, another record-breaking number, ASE chief operating officer Tien Wu
The EU and US are nearing an agreement to coordinate on producing and securing critical minerals, part of a push to break reliance on Chinese supplies. The potential deal would create incentives, such as minimum prices, that could advantage non-Chinese suppliers, according to a draft of an “action plan” seen by Bloomberg. The EU and US would also cooperate on standards, investments and joint projects, as well as coordinate on any supply disruptions by countries like China. The two sides are additionally seeking other “like-minded partners” to join a multicountry accord to help create these new critical mineral supply chains, which feed into
For weeks now, the global tech industry has been waiting for a major artificial intelligence (AI) launch from DeepSeek (深度求索), seen as a benchmark for China’s progress in the fast-moving field. More than a year has passed since the start-up put Chinese AI on the map in early last year with a low-cost chatbot that performed at a similar level to US rivals. However, despite reports and rumors about its imminent release, DeepSeek’s next-generation “V4” model is nowhere in sight. Speculation is also swirling over the geopolitical implications of which computer chips were chosen to train and power the new
TECH WINNERS: Taiwan and South Korea reported robust trade, which suggests that they have critical advantages in the rapidly expanding AI supply chain, an official said Exports last month surged to a new high, as booming demand tied to artificial intelligence (AI) infrastructure fueled shipments of advanced technology components, underscoring the nation’s pivotal role in the global semiconductor supply chain. Outbound shipments climbed to US$80.18 billion, the highest ever for a single month, rising 61.8 percent from a year earlier and marking the 29th consecutive month of growth, the Ministry of Finance said yesterday. “The surge was driven primarily by global investment in AI infrastructure,” Department of Statistics Director-General Beatrice Tsai (蔡美娜) said. The mass production of next-generation AI computing systems has accelerated procurement across the semiconductor supply
RSS